Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients

Purpose The purpose of this study was to investigate the clinical features of epithelial ovarian cancer (EOC) patients according to BRCA1/2 mutation status (mutation, variant of uncertain significance [VUS], or wild type). Materials and Methods We analyzed 116 patients whose BRCA1/2 genetic test results were available for mutation type and clinical features, including progression-free survival (PFS), overall survival (OS), and response rate. These characteristics were compared according to BRCA1/2 mutation status. Results Thirty-seven (37/116, 31.9%) BRCA1/2mutations were identified (BRCA1, 30; BRCA2, 7). Mutation of c.3627_3628insA (p.Leu1209_Glu1210?fs) in BRCA1 was observed in five patients (5/37, 13.5%). Twenty-five patients had BRCA1/2 VUSs (25/116, 21.6%). Personal histories of breast cancer were observed in 48.6% of patients with BRCA1/2 mutation (18/37), 16.0% of patients with BRCA1/2 VUS (4/25), and 7.4% of patients with BRCA wild type (4/54) (p < 0.001). Patients with BRCA1/2 mutation showed longer OS than those with BRCA1/2 wild type (p=0.005). No significant differences were detected in PFS, OS, or response rates between patients with BRCA1/2 VUS and BRCA1/2 mutation (p=0.772, p=0.459, and p=0.898, respectively). Conclusion Patientswith BRCA1/2 mutation had longer OS than thosewith BRCA1/2wild type. Patients with BRCA1/2 mutation and BRCA1/2 VUS displayed similar prognoses.

[1]  P. Johnston,et al.  BRCA1 mRNA Expression Levels Predict for Overall Survival in Ovarian Cancer after Chemotherapy , 2007, Clinical Cancer Research.

[2]  Jae Hoon Kim,et al.  Germline mutations of BRCA1 and BRCA2 in Korean sporadic ovarian carcinoma. , 2005, Gynecologic oncology.

[3]  L. Meng,et al.  The Role of BRCA Status on the Prognosis of Patients with Epithelial Ovarian Cancer: A Systematic Review of the Literature with a Meta-Analysis , 2014, PloS one.

[4]  T Takahashi,et al.  Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  A. Ashworth,et al.  The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability , 2006, Oncogene.

[6]  X. Wang,et al.  Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. , 1999, Molecular cell.

[7]  S. Neuhausen,et al.  Prevalence of BRCA Mutations and Founder Effect in High-Risk Hispanic Families , 2005, Cancer Epidemiology Biomarkers & Prevention.

[8]  B. Rosen,et al.  Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status. , 2016, Gynecologic oncology.

[9]  Sung-Won Kim,et al.  The Korean Hereditary Breast Cancer Study: Review and Future Perspectives , 2013, Journal of breast cancer.

[10]  Sean V Tavtigian,et al.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Y. Won,et al.  Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012 , 2015, Journal of gynecologic oncology.

[12]  S. Tsuji,et al.  Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  F. Muggia,et al.  'BRCAness' and its implications for platinum action in gynecologic cancer. , 2014, Anticancer research.

[14]  Jun Mo Lee,et al.  Germline Mutations of BRCA1 and BRCA2 in Korean Ovarian Cancer Patients: Finding Founder Mutations , 2015, International Journal of Gynecologic Cancer.

[15]  K. Hess,et al.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. , 2011, JAMA.

[16]  T. Sellers,et al.  Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. , 2013, Journal of the National Cancer Institute.

[17]  L. Esserman,et al.  Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. , 2005, JAMA.

[18]  M. Ausems,et al.  Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer , 2007, Genetics in Medicine.

[19]  S. Gayther,et al.  The Contribution of BRCA1 and BRCA2 to Ovarian Cancer , 2009, Molecular oncology.

[20]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[21]  Leif E. Peterson,et al.  Characterization of BRCA1 and BRCA2 mutations in a large United States sample. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  B. Ponder,et al.  Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. , 1999, Cancer research.

[23]  K. Hess,et al.  Association of BRCA 1 and BRCA 2 Mutations With Survival , Chemotherapy Sensitivity , and Gene Mutator Phenotype in Patients With Ovarian Cancer , 2011 .

[24]  J. Ranstam,et al.  Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Fergus J Couch,et al.  A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. , 2007, American journal of human genetics.

[26]  D. Levine,et al.  Cell proliferation and apoptosis in BRCA-associated hereditary ovarian cancer. , 2002, Gynecologic oncology.

[27]  Alan Ashworth,et al.  BRCAness revisited , 2016, Nature Reviews Cancer.

[28]  Wen-Hwa Lee,et al.  BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. , 2002, Science.

[29]  S. Kong,et al.  BRCA1 and BRCA2 germline mutations in Korean ovarian cancer patients , 2009, Journal of Cancer Research and Clinical Oncology.

[30]  A. Russo,et al.  The Clinical Significance of Unknown Sequence Variants in BRCA Genes , 2010, Cancers.